White Paper

In Their Lifetime: Outlook For Rare Disease And Orphan Drug Research

Source: Medpace
Rare Disease

Collectively rare diseases comprise a large segment of the global population. Developing effective treatments to combat these diseases demand heavy resources from biopharmaceutical companies - both monetary and scientific. Even though these diseases are singularly rare, the combination of governmental incentives to develop compounds for potential success, combined with public support to find cures for these diseases make the practice of R&D for Rare Diseases-Orphan Drug one of the fastest growing segments in the biopharmaceutical industry.